Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Sadat City University

Overview

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Schizophrenia Dyslipidemias

Interventions

Vildagliptin 50 MGDRUG

Vildagliptin 50 MG tablet once daily

PlaceboDRUG

Placebo one tablet daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60. Exclusion Criteria: * liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus

Locations (1)

Faculty of Pharmacy

Shibīn al Kawm, Menoufia, Egypt

Outcomes

Primary Outcomes

low-density lipoprotein cholesterol

Time frame: week 12

Secondary Outcomes

high-density lipoprotein cholesterol

Time frame: week 12

Serum stem cell growth factor beta

Time frame: week 12

FAM19A5 serum level

Time frame: 12 weeks

TNF-alpha serum level

Time frame: 12 weeks

Adverse drug reactions

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.